We are live on ! Find out more
GLUE icon

Monte Rosa Therapeutics
GLUE

56 hedge funds and large institutions have $759M invested in Monte Rosa Therapeutics in 2021 Q3 according to their latest regulatory filings, with 28 funds opening new positions, 6 increasing their positions, 13 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

40% more first-time investments, than exits

New positions opened: 28 | Existing positions closed: 20

17% more funds holding

Funds holding: 48 → 56 (+8)

8% more capital invested

Capital invested by funds: $705M → $759M (+$54.3M)

3.09% more ownership

Funds ownership: 72.14% → 75.23% (+3.1%)

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

54% less repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 13

Holders
56
Holders Change
+8
Holders Change %
+16.67%
% of All Funds
0.98%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
28
Increased
6
Reduced
13
Closed
20
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$75.8M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$26.4M
3
BlackRock
BlackRock
New York
+$14.9M
4
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$11.7M
5
Geode Capital Management
Geode Capital Management
Massachusetts
+$5.61M

Top Sellers

Rank Fund Capital Flow
1
DM
Deerfield Management
New York
-$7.95M
2
O
OrbiMed
New York
-$7.95M
3
LGM
Logos Global Management
California
-$7.17M
4
SCM
Suvretta Capital Management
New York
-$3.4M
5
SAM
Sectoral Asset Management
Quebec, Canada
-$2.94M
Name Holding Trade Value Shares
Change 		Change in
Stake
LGM
26
Logos Global Management
California
$1.11M -$7.17M -250,000 -83%
CCM
27
CAAS Capital Management
New York
$1.11M – – –
D.E. Shaw & Co
28
D.E. Shaw & Co
New York
$1.05M +$1.35M +47,124 New
TD Asset Management
29
TD Asset Management
Ontario, Canada
$864K – – –
Citadel Advisors
30
Citadel Advisors
Florida
$836K -$1.67M -58,243 -61%
Bank of New York Mellon
31
Bank of New York Mellon
New York
$621K +$798K +27,856 New
SCM
32
Soleus Capital Management
Connecticut
$557K -$1.43M -50,000 -67%
Goldman Sachs
33
Goldman Sachs
New York
$426K -$2.56M -89,381 -82%
N
34
Nuveen
North Carolina
$373K +$480K +16,754 New
GCM
35
Ghisallo Capital Management
Massachusetts
$334K -$143K -5,000 -25%
CSS
36
Cubist Systematic Strategies
Connecticut
$239K +$308K +10,731 New
RhumbLine Advisers
37
RhumbLine Advisers
Massachusetts
$206K +$265K +9,233 New
Deutsche Bank
38
Deutsche Bank
Germany
$171K +$221K +7,698 New
SG Americas Securities
39
SG Americas Securities
New York
$161K +$207K +7,238 New
AIG
40
American International Group
New York
$141K +$182K +6,333 New
California State Teachers Retirement System (CalSTRS)
41
California State Teachers Retirement System (CalSTRS)
California
$139K +$179K +6,252 New
MIM
42
MetLife Investment Management
New Jersey
$106K +$136K +4,756 New
JP Morgan Chase
43
JP Morgan Chase
New York
$99K +$127K +4,432 New
New York State Common Retirement Fund
44
New York State Common Retirement Fund
New York
$91K +$118K +4,100 New
MLICM
45
Metropolitan Life Insurance Company (MetLife)
New York
$80.2K +$103K +3,598 New
SO
46
STRS Ohio
Ohio
$60K +$77.4K +2,700 New
PSC
47
Piper Sandler & Co
Minnesota
$51K +$65.9K +2,300 New
TRCT
48
Tower Research Capital (TRC)
New York
$31K +$28.2K +985 +246%
Royal Bank of Canada
49
Royal Bank of Canada
Ontario, Canada
$29K +$36.7K +1,279 New
Citigroup
50
Citigroup
New York
$29K +$37.9K +1,321 New
1
2
3 4

GLUE Hedge Fund Activity: Q3 2021 in Review

56 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Monte Rosa Therapeutics (GLUE) for Q3 2021, worth a combined $759M — up 7.7% from $705M a quarter earlier.

Buyers outnumbered sellers: 28 funds opened new GLUE positions and 20 closed out — a net gain of 8 holders — while 6 added to existing stakes and 13 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $75.8M. The largest seller was Deerfield Management, exiting entirely with an estimated $7.95M sold.

  • 56 institutional investors held Monte Rosa Therapeutics (GLUE) as of Q3 2021, up from 48 in Q2 2021.
  • Funds reported $759M of Monte Rosa Therapeutics stock for Q3 2021, up 7.7% quarter-over-quarter.
  • 28 funds opened new Monte Rosa Therapeutics positions in Q3 2021 and 20 closed out, a net change of +8 holders.
  • The largest Monte Rosa Therapeutics buyer in Q3 2021 was Fidelity Investments, an estimated $75.8M added.
  • The largest Monte Rosa Therapeutics seller in Q3 2021 was Deerfield Management, an estimated $7.95M sold.

Based on aggregated 13F filings for Q3 2021.